DRD5 Gene — Dopamine Receptor D5
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">dr5</th>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q35.1</td>
</tr>
<tr>
<td class="label">Amino acids</td>
<td>446</td>
</tr>
<tr>
<td class="label">D5 has 31 additional residues in C-terminus</td>
<td>| D5 has higher basal activity (constitutive activity)</td>
</tr>
<tr>
<td class="label">D5 has higher dopamine affinity (~10-fold)</td>
<td>| D5 mRNA shows more widespread brain distribution</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">72 edges</a></td>
</tr>
</table>
Overview
DRD5 (Dopamine Receptor D5, NCBI Gene ID: 1816, OMIM: [126453](https://www.omim.org/entry/126453), UniProt: [P21918](https://www.uniprot.org/uniprot/P21918), Ensembl: [ENSG00000169679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169679)) encodes the D5 dopamine receptor, a G protein-coupled receptor (GPCR) belonging to the D1-like family of dopamine receptors. DRD5 exhibits the highest dopamine affinity among all dopamine receptor subtypes and is coupled primarily to Gαs proteins that stimulate adenylyl cyclase[@sunahara1991]. Located on chromosome 4p16.1, DRD5 is expressed broadly across the brain with highest densities in the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [striatum](/brain-regions/striatum), and [substantia nigra](/brain-regions/substantia-nigra). The receptor plays essential roles in cognitive function, motor control, circadian rhythm regulation, and reward-motivated behavior. Dysregulation of DRD5 signaling is implicated in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [schizophrenia](/diseases/schizophrenia), and various movement disorders[@chen2019].
Unlike D2-like receptors (DRD2, DRD3, DRD4) which couple to Gαi and inhibit cAMP production, D5 receptors activate Gαs-mediated signaling cascades that increase intracellular cAMP, activate protein kinase A (PKA), and modulate downstream effectors including ion channels, transcription factors, and synaptic proteins[@sibley1999]. This signaling profile positions DRD5 as a key modulator of excitatory dopaminergic responses in neural circuits.
Gene Structure and Protein Architecture
Genomic Organization
The human DRD5 gene spans approximately 4.3 kb on chromosome 4p16.1 and consists of 2 coding exons. The gene encodes a 477 amino acid protein with a molecular weight of approximately 52.9 kDa. DRD5 is closely linked to DRD1 on chromosome 4, suggesting a common evolutionary origin through gene duplication.
Protein Structure
The D5 receptor is a typical GPCR with seven transmembrane helices (TM1-TM7):
- N-terminal extracellular domain: Contains glycosylation sites, involved in ligand binding
- Transmembrane domains (TM1-TM7): Form the binding pocket for dopamine and synthetic ligands
- Three extracellular loops (ECL1-ECL3): Modulate ligand access and receptor conformation
- Three intracellular loops (ICL1-ICL3): Couple to G proteins and contain regulatory phosphorylation sites
- C-terminal intracellular tail: Contains serine/threonine residues for PKA phosphorylation and PDZ-binding motifs
Comparison with D1 Family
Molecular Function and Signal Transduction
G Protein Coupling and Signaling Pathways
DRD5 couples primarily to Gαs proteins, initiating the following cascade[@berthaus2004]:
Primary signaling (Gs-coupled):
Dopamine binding induces receptor conformational change
Gαs-GTP complex exchanges GDP for GTP
Gαs-GTP stimulates adenylyl cyclase (AC)
Increased cAMP production from ATP
Protein kinase A (PKA) activation
Phosphorylation of downstream targets (ion channels, transcription factors, kinases)Secondary signaling pathways:
- Gβγ signaling: Gβγ subunits can activate phospholipase C-β (PLC-β)
- MAPK pathway: D5 receptors can activate ERK1/2 through PI3K
- Calcium signaling: D5-mediated depolarization affects voltage-gated calcium channels
Constitutive Activity
A distinctive feature of DRD5 is its significant constitutive (ligand-independent) activity[@greengard2001]:
- The receptor adopts an active conformation even without dopamine bound
- Results in basal cAMP production in the absence of ligand
- Makes the receptor a tonic signal generator, not just a response amplifier
- Has implications for drug development — neutral antagonists vs. inverse agonists
Signal Termination
Signal is terminated through multiple mechanisms:
- Receptor internalization: β-arrestin-mediated endocytosis
- Phosphorylation: GRKs phosphorylate the receptor, uncoupling from G proteins
- Desensitization: PKA-mediated phosphorylation reduces coupling efficiency
- Receptor downregulation: Prolonged agonist exposure reduces receptor density
Brain Expression and Localization
Regional Distribution
DRD5 shows a broader anatomical distribution than DRD1[@richfield1999]:
High expression regions:
- Cerebral cortex: Particularly in prefrontal cortex (layer 5 pyramidal neurons)
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Striatum: Co-localizes with DRD1 in direct pathway medium spiny neurons
- Substantia nigra pars compacta: Dopaminergic neurons (autoreceptor function)
- Dentate nucleus of cerebellum: Deep cerebellar nucleus neurons
Moderate expression regions:
- Globus pallidus (external segment): GPe neurons
- Thalamus: Specific relay nuclei
- Hypothalamus: Arcuate nucleus and periventricular regions
- Superior colliculus: Layers involved in visual processing
Lower expression:
- Amygdala: Scattered expression in central nucleus
- Brainstem: Reticular formation areas
Subcellular Localization
DRD5 is primarily localized to:
- Dendritic shafts and spines: Post-synaptic density of excitatory synapses
- Somatic plasma membrane: Perisynaptic regions
- Axon terminals: Presynaptic localization (some neurons — autoreceptor)
- Intracellular vesicles: Trafficking between endosomes and plasma membrane
Cell Type Specificity
Within brain regions, DRD5 is expressed in:
- Excitatory glutamatergic neurons: Pyramidal cells of cortex and hippocampus
- Medium spiny neurons (MSNs): Striatal GABAergic neurons of the direct pathway
- Dopaminergic neurons: Nigral neurons (atypical — usually D2 serves as autoreceptor)
- Interneurons: Some parvalbumin-positive basket cells in cortex
Physiological Roles
Motor Control
DRD5 plays critical roles in basal ganglia circuitry[@hanley2010]:
Direct pathway activation (with DRD1):
Cortex → Striatum (D1/D5 MSNs) → GPi/SNr → Thalamus → Cortex
↑ D1/D5 activation inhibits indirect pathway, facilitates movement
D1/D5 receptor activation on direct pathway MSNs:
- Excites neurons projecting to internal segment of globus pallidus (GPi)
- Inhibits GPi output to thalamus
- Disinhibits thalamocortical neurons
- Facilitates initiated movements
In Parkinson's disease: Loss of nigral dopamine reduces D1/D5 activation, leading to:
- Reduced direct pathway activity
- Excessive indirect pathway inhibition
- Movement initiation failure (bradykinesia)
Cognitive Function
DRD5 modulates several cognitive domains:
Working memory:
- Prefrontal cortex D5 receptors enhance persistent firing of delay cells
- Required for maintaining information across delay periods
- D5/D1 activation in PFC layers 2/3 and 5 supports spatial working memory
Attention and executive function:
- D5 receptor activity in anterior cingulate cortex
- Supports task-switching and conflict monitoring
- D5 polymorphisms associated with attention deficit symptoms
Learning and memory:
- Hippocampal D5 receptors contribute to long-term potentiation (LTP)
- D5 activation enhances NMDA receptor function
- Contributes to reward learning and memory consolidation
Circadian Rhythm
DRD5 is expressed in the suprachiasmatic nucleus (SCN) and modulates circadian clock function:
- D5/D1 receptors in SCN neurons respond to dopamine released from the intergeniculate leaflet
- Controls photic and non-photic entrainment of the circadian clock
- D5 signaling affects clock gene expression (PER1, PER2)
- Implications for sleep disorders and clock-related neurodegeneration
Reward and Motivation
While DRD5 is not the primary reward receptor (DRD1 and DRD2 dominate mesolimbic reward), DRD5 contributes:
- Reinforcement of reward-related behaviors
- Modulation of reward magnitude
- Interaction with emotional processing circuits
Disease Associations
Parkinson's Disease
DRD5 plays complex roles in [Parkinson's disease](/diseases/parkinsons-disease)[@mishina2012]:
Pathophysiological involvement:
- D5 receptors are relatively spared compared to D2 receptors in PD
- Remaining D5 activity contributes to motor reserve
- D5/D1 heterodimerization may influence response to levodopa therapy
Therapeutic implications:
- D1/D5 agonists (bromocriptine, pergolide) used in early PD
- D1/D5 receptor density affects levodopa response duration
- Wearing-off phenomena may involve D5 receptor desensitization
Genetic studies:
- DRD5 polymorphisms have been investigated for PD risk
- Some studies suggest DRD5 variants modify PD susceptibility
- Haplotype analysis reveals modest but reproducible associations
Alzheimer's Disease
Emerging evidence links DRD5 to [Alzheimer's disease](/diseases/alzheimers-disease) pathology[@yang2019]:
Mechanisms:
- Dopaminergic dysfunction occurs early in AD, before motor symptoms
- D5 receptors modulate hippocampal plasticity — affected in AD
- D5 signaling interacts with amyloid-beta and tau pathology
Cognitive impairment:
- D5/D1 dysfunction contributes to working memory deficits in AD
- Cholinergic-dopaminergic interaction in memory circuits
- D5 receptor density declines with age and AD progression
Therapeutic approaches:
- Dopamine replacement shows modest cognitive benefits in AD
- D1/D5 agonists being investigated for AD cognitive symptoms
- Combination with cholinesterase inhibitors under study
Schizophrenia
DRD5 is implicated in [schizophrenia](/diseases/schizophrenia) pathophysiology[@luo2018]:
Dopamine hypothesis refinement:
- Hyperactive dopamine transmission in mesolimbic pathway
- D2 receptors mediate positive symptoms (hallucinations, delusions)
- D1/D5 dysfunction in prefrontal cortex mediates negative symptoms and cognitive deficits
Prefrontal cortex dysfunction:
- Reduced D1/D5 signaling in PFC causes working memory deficits
- Low D1/D5 tone may underlie negative symptoms (avolition, flat affect)
- Genetic variants affecting D5 expression modify schizophrenia risk
Antipsychotic drug actions:
- All antipsychotics block D2 receptors primarily
- Some atypical antipsychotics (clozapine, quetiapine) have higher D5:D2 affinity ratios
- May explain superior efficacy for negative and cognitive symptoms
Movement Disorders
Dystonia:
- D5 receptor mutations associated with focal dystonia
- DRD5 variants in writer's cramp and blepharospasm
- D1/D5 dysfunction in basal ganglia causes excessive involuntary movements
Tourette Syndrome:
- DRD5 polymorphisms associated with tic disorders
- D5/D1 hyperactivity in cortico-striato-thalamo-cortical circuits
- D1/D5 antagonists partially reduce tic severity
Huntington's Disease:
- D5/D1 receptor loss in striatum correlates with chorea severity
- Early HD shows preserved D5/D1; late HD shows significant loss
Molecular Mechanisms
Receptor Dimerization
DRD5 forms heteromers with other GPCRs, creating unique signaling properties[@seutin2005]:
- DRD5-DRD1 heteromers: Physical interaction between D1 and D5 creates a "super-receptor" with enhanced G-protein coupling and biased signaling
- DRD5-DRD2 complexes: In some neurons, D5-D2 complexes modulate cross-talk between D1-like and D2-like signaling
- A2A-D5 interactions: Adenosine A2A and D5 receptors form functional heteromers, affecting striatal signaling
Interactions with Other Proteins
DRD5 interacts with numerous scaffolding and signaling proteins:
- β-arrestin 1/2: Internalization, biased signaling
- AKAP150/79: Targeting PKA to the receptor complex
- DARPP-32: Key signaling hub in striatal neurons
- PSD-95 family: Postsynaptic density anchoring
- RGS proteins: Regulators of G protein signaling
DARPP-32 Pathway
DRD5 activation in striatal neurons activates the DARPP-32 cascade[@greengard2001]:
Mermaid diagram (expand to render)
Therapeutic Targeting
Agonists
Non-selective D1/D5 agonists:
- Dihydrexidine (DAR-0100): Full D1/D5 agonist, investigated for PD and schizophrenia cognitive symptoms
- SKF81297: Research tool, high D1/D5 selectivity
- A-77636: D1/D5 agonist with long duration of action
Clinical use considerations:
- D1/D5 agonists cause significant hypotension (vasodilatory effect)
- CNS penetration is challenging — many compounds are substrates for P-glycoprotein
- Tachyphylaxis develops with continued use
Antagonists
Clinical antipsychotics with D1/D5 activity:
- Clozapine: Highest D5:D2 affinity ratio among approved drugs
- Quetiapine: Blocks D5 along with D2; better cognitive profile
- Fluphenazine: High D1/D5 blockade
Research compounds:
- SCH23390: First selective D1/D5 antagonist, research standard
- SKL83556: High-affinity D1/D5 antagonist with CNS penetration
Allosteric Modulators
- PAI-1 (D1/D5 positive allosteric modulator): Increases affinity for dopamine
- BBR-1: D1/D5 negative allosteric modulator
Genetic Variants and Polymorphisms
Common Variants
- rs77497769: Promoter variant affecting transcription
- rs6283: Missense variant (Pro310Leu) with reduced coupling efficiency
- rs2075652: Intron variant associated with schizophrenia in GWAS
- rs1800762: 5' UTR variant affecting translation
Rare Pathogenic Variants
- Benign hereditary chorea: Some DRD5 variants cause early-onset movement disorder
- Myoclonus-dystonia: Rare DRD5 mutations in some families
- Tourette syndrome: Rare DRD5 variants found in severe cases
Animal Models
Knockout Mice
Drd5 null mice:
- Viable and fertile — no developmental abnormalities
- Reduced locomotor response to D1/D5 agonists
- Impaired working memory in Morris water maze
- Altered circadian phase-shifting
Conditional knockouts:
- Forebrain-specific Drd5 KO reproduces cognitive phenotypes
- Striatal-specific KO affects motor learning
Transgenic Models
- DRD5 overexpression: Increases basal activity, causes hyperactivity
- Constitutively active DRD5: Mimics agonist stimulation without ligand
See Also
- [Dopamine Receptors](/entities/dopamine-receptors) — receptor family overview
- [DRD1 Gene](/genes/drd1) — closely related D1 receptor
- [DRD2 Gene](/genes/drd2) — D2 receptor, primary target in PD treatment
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD and dopamine signaling
- [Alzheimer's Disease](/diseases/alzheimers-disease) — cognitive symptoms and dopamine
- [Schizophrenia](/diseases/schizophrenia) — dopamine hypothesis and treatment
- [Dopamine Signaling](/mechanisms/dopamine-signaling-pathway) — detailed signaling pathways
- [Basal Ganglia Circuits](/mechanisms/basal-ganglia-circuits) — motor control and disease
- [GPCR Signaling in Neurodegeneration](/mechanisms/gpcr-signaling-neurodegeneration) — GPCR mechanisms
External Links
- [NCBI Gene 1816](https://www.ncbi.nlm.nih.gov/gene/1816)
- [OMIM 126453](https://www.omim.org/entry/126453)
- [UniProt P21918](https://www.uniprot.org/uniprot/P21918)
- [Ensembl ENSG00000169679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169679)
- [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/ObjectDetailsForward?name=DRD5&objectClass=receptor)
- [GeneCards DRD5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DRD5)
Pathway Diagram
The following diagram shows the key molecular relationships involving DRD5 Gene — Dopamine Receptor D5 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)